Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis
批准号:
10084212
负责人:
Thomas S Griffith
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-10-01 至 2021-12-31
关键词:
Acquired Immunodeficiency SyndromeAcuteAdaptive Immune SystemAffectAgingAmericanAntibody FormationAutomobile DrivingAwardB-LymphocytesBackBacterial InfectionsCD4 Positive T LymphocytesCause of DeathCell CountCell physiologyCellsCessation of lifeChronicChronic PhaseDataDefectDendritic CellsDiagnostic ProcedureElderlyEventFunctional disorderGenerationsGoalsGoldHealthcare SystemsHospitalsHumanHumoral ImmunitiesImmuneImmune System DiseasesImmune responseImmunityImmunizationImmunologicsImmunosuppressionImmunosuppressive AgentsImpairmentIncidenceInfectionIntra-abdominalInvestigationLeadLymphopeniaMaintenanceMalignant neoplasm of prostateMeasuresMicrobeModelingMulti-Drug ResistanceNosocomial InfectionsOpportunistic InfectionsPaperPatientsPeritonitisPhasePopulationPositioning AttributePredispositionPublicationsPublishingQuality of lifeRecoverySecondary ImmunizationSecondary toSepsisStandard ModelSupporting CellSurvivorsT-LymphocyteTestingTherapeuticTherapeutic procedureToxinadaptive immune responseadaptive immunitybasececal ligation puncturecombatexperienceextracellularhigh risk populationimmune system functioninnovationmalignant breast neoplasmmemory CD4 T lymphocytemicrobialmortalitymouse modelnovel therapeuticsolder patientpathogenpolymicrobial sepsispreventresponserestorationsecondary infectionsepticseptic patientssocioeconomicstherapy design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Sepsis causes more deaths in U.S. hospitals annually than prostate cancer, breast cancer, and AIDS
combined. Elderly patients are a particularly high-risk group, with an incidence rate of ~60% of all septic cases.
The elderly are also extremely vulnerable to the consequences of sepsis, showing 100-fold higher mortality
than younger patients. Some of these deaths occur acutely after sepsis, but ~70% of these patients survive the
initial infection, and succumb to opportunistic infections during the chronic phase of sepsis. The chronic stage
of sepsis is important and is characterized by immunosuppression, but little is known about the mechanisms of
sepsis-induced immunosuppression.
CD4 T cells, essential for coordinating immune responses to a range of pathogens, are severely depleted
during the acute stage of sepsis, and gradually recover throughout the immunosuppressive phase of sepsis.
Our recent publication included data showing certain Ag-specific CD4 T cell populations do not recover,
despite quantitative restoration of total CD4 T cells. We suspect that the prolonged loss of Ag-specific CD4 T
cells introduces “gaps” within the T cell repertoire leading to overall decreased adaptive immune system
function. Among the immunological settings where CD4 T cell function is vital, this proposal will define the
mechanisms responsible for the impairment of CD4 T cell-dependent B cell responses using the CLP model
followed by secondary immunization or heterologous pathogen infection. Accordingly, our central hypothesis
holds that alterations in the number and function of both follicular helper CD4 T (Tfh) cells and B cells after
sublethal CLP-induced sepsis is responsible for suppressed humoral immunity and reduced protection against
pathogens encountered within the context of localized or systemic secondary infections.
The following specific aims will test our hypothesis: Aim 1) Define the sepsis-induced defects in Ag-specific
CD4 T cells and B cells that restrict the generation of a productive CD4 T cell-dependent B cell response; Aim
2) Investigate the ability of therapies designed to restore DC or B cell number and function to revitalize humoral
immunity after sepsis; and Aim 3) Determine the impact of sepsis on the maintenance and function of pre-
existing memory CD4 T cells and B cells. Ultimately, this proposal will increase our understanding of why
septic patients are more susceptible to secondary infections. Our use of the CLP model of polymicrobial sepsis,
our ability to identify and study the function of endogenous Ag-specific CD4 T cells and B cells, and our
experience measuring the adaptive immune response to infectious pathogens put us in the perfect position to
define the mechanism(s) driving sepsis-induced suppression of CD4 T cell-dependent B cell immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLRD Research Career Scientist Award Application
-
批准号:10582394
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Thomas S Griffith
-
依托单位:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
-
批准号:10257687
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
CD4 T cell dysfunction and reprogramming during sepsis
-
批准号:10633073
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
-
批准号:10413143
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
-
批准号:10512750
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
-
批准号:10237569
-
项目类别:
-
资助金额:$23.24万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
CD4 T cell dysfunction and reprogramming during sepsis
-
批准号:10400169
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2021
-
负责人:Thomas S Griffith
-
依托单位:
Alterations in CD4 T cells during sepsis
-
批准号:9101373
-
项目类别:
-
资助金额:$31.59万
-
财政年份:2016
-
负责人:Thomas S Griffith
-
依托单位:
Suppression of T cell immunity during sepsis
-
批准号:8601255
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Suppression of T cell immunity during sepsis
-
批准号:8237299
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Using microbially-experienced mice to study the innate immune response in sepsis
-
批准号:10655287
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Using microbially-experienced mice to study the innate immune response in sepsis
-
批准号:10367761
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:Thomas S Griffith
-
依托单位:
Apoptotic cells induce tolerance through TRAIL-expressing CD8+ regulatory T cells
-
批准号:7892840
-
项目类别:
-
资助金额:$37.19万
-
财政年份:2009
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL: A MECHANISM FOR BCG-INDUCED ANTI-TUMOR ACTIVITY IN BLADDER CANCER
-
批准号:7604865
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2007
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:7227055
-
项目类别:
-
资助金额:$25.8万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:8255342
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:7851372
-
项目类别:
-
资助金额:$26.88万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:6901940
-
项目类别:
-
资助金额:$27.21万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
Recombinant Immunotherapy for Renal Cell Carcinoma
-
批准号:6816995
-
项目类别:
-
资助金额:$27.21万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
-
批准号:8484212
-
项目类别:
-
资助金额:$24.29万
-
财政年份:2004
-
负责人:Thomas S Griffith
-
依托单位:
海外基金